Exchange: NASDAQ·Updated 03:59 PM EST

NAII News

News
all
press releases
Natural Alternatives Q4 Loss Widens Y/Y on Margin Pressure
NAII posts y/y sales growth in Q4'26, but a $10.4M impairment charge and factory underutilization weigh on profitability.
Zacks
Natural Alternatives Q4 Loss Widens Y/Y on Margin Pressure
NAII posts y/y sales growth in Q4'26, but a $10.4M impairment charge and factory underutilization weigh on profitability.
Zacks
More News
NHTC, HCWC, and NAII sell into the growing nutrition and wellness space.
Zacks
NAII's Q3 sales rise 23% y/y, but a wider loss and margin pressure offset gains from stronger contract manufacturing demand.
Zacks
NAII posts higher Q2 sales but wider losses, and trims its outlook for fiscal 2026 amid softer customer forecasts and launch delays.
Zacks
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.
Zacks
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates CFFI as "Neutral." Explore how Natural Alternatives' expansion, innovation and prudent management balance growth potential with margin and execution challenges in a dynamic supplement market.
Zacks
NAII sales rise y/y in the fourth quarter of fiscal 2025, but higher charges and underused capacity widen loss.
Zacks

Advertisement|Remove ads.